About this policy
The comment period for the MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer DL39042 Local Coverage Determination (LCD) began on 05/20/2021 and ended on 07/03/2021. The notice period for L39042 begins on 05/19/2022 and will become effective on 07/03/2022. The title of the LCD was revised from MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer to MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer. The comments below were received from the provider community.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.